ASCO GU 2024

Combination vs. monotherapy - a great new option for high-risk patients

Cabo + IO: Interesting but not practice changing?!

BRCAAway - practice changing or hypothesis generating data?

Is "more" always better?

BRCAaway - PARP combination study

Therapy Intensification Still Neglected in mHSPC

Gleason 3+3 - cancer or not?

Insights and news for mCRPC

Combination NHT + PARP makes sense

Higher radiation is effective in high-risk PCA

Long-term dose escalation - Therapy in high-risk prostate cancers

Olaparib + Arbiraterone better compared to either alone

Relugolix combined with androgen signaling in real word experience

What about the clinical benefit?

Enzalutamide therapy as option for biochemical recurrence

Further testing before olaparib combination

Dose de-escalation in different ways

Still a difficult time for androgenic inhibitors in mCRPC

Evaluating the recombination-repair mutations in patients with mCRPC

Stockholm3 validated in multiethnic cohort

Localized PCa - news for radiotherapy and biochemical recurrence

Cognitive function in ART treatment

Salvage radiation with anti-androgen superior to radiation alone

Quality of life under intensive therapy

Combination of cabozantinib & checkpoint inhibitor

First positive study of IO therapy in mCRPC

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

BRCAAway - PARP hämmare, abiraterone eller i kombination

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Kombination av cabozantinib och immunterapi

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Gleason 3+3 ska vi kalla de cancer eller inte?

Kognitiv påverkan av abirateron och enzalutamid?

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial cancer

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Update on EV-302

Pembrolizumab adjuvant in bladder cancer

Update M1 urothelial cancer

Another success for an ICI?

EV + Pembro new first-line standard in localized metastatic bladder cancer

EV as standard in 3rd line mUC

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Perioperative adjuvant therapy in urothelial cancer

ASCO GU24 - Highlights in Bladder cancer

MIBC: adjuvant PD1 - all set?!

Highlights in bladder cancer at ASCO GU24

Biomarker update

HER2 and bladder cancer

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Subcutaneous vs. intravenous application: ready for everyday clinics?

No surprise with the QoL data

Tumorburden and outcome

Long-term outcome

Long-term follow-up of first-line trials

ASCO GU24 - Highlights in renal cell carcinoma

Long-Term Data on NIVO+IPI in aRCC

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Practice changing adjuvant therapy?!

Durable effects of Ipi-Nivo

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Highlights in kidney cancer at ASCO GU24

Overall survival benefit - Pembro after surgery

Belzutifan: Updates on QoL

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Better QoL with Belzutifan

Perioperative treatment in renal cell carcinoma - did we close the circle?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?